Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. 1977

R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick

The synthetic prostaglandin analog 9,11-azoprosta-5,13-dienoic acid (azo analog I) has been found to be a potent inhibitor of human platelet thromboxane synthetase by three independent analytical methods: electron-capture gas chromatography, radioisotopic thin-layer chromatography, and radioimmunoassay. In the presence of azo analog I, human platelet aggregation induced by either the prostaglandin endoperoxide PGH2 or arachidonic acid was antagonized. The addition of azo analog I shifted the transformation of endoperoxides away from thromboxane synthesis and toward prostaglandin E2 synthesis. The specificity of azo analog I is demonstrated by its selective inhibition of the second wave of either ADP- or epinephrine-induced platelet aggregation. These data indicate that PGH2 must be converted to thromboxane A2 in order to induce human platelet aggregation.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011463 Prostaglandins H A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001095 Arachidonic Acids Eicosatetraenoic Acids,Acids, Arachidonic,Acids, Eicosatetraenoic

Related Publications

R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
March 1978, Biochimica et biophysica acta,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
July 1983, Biochemical pharmacology,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
January 1983, British journal of clinical pharmacology,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
August 1981, Prostaglandins,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
October 1987, Biochemical and biophysical research communications,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
January 1985, Stroke,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
March 1987, Lancet (London, England),
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
August 1988, Lancet (London, England),
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
January 1987, Free radical research communications,
R R Gorman, and G L Bundy, and D C Peterson, and F F Sun, and O V Miller, and F A Fitzpatrick
June 1984, FEBS letters,
Copied contents to your clipboard!